Aprocitentan Patent Expiration

Aprocitentan was first introduced by Idorsia Pharmaceuticals Ltd in its drug Tryvio on Mar 19, 2024.


Aprocitentan Patents

Given below is the list of patents protecting Aprocitentan, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tryvio US10919881 Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan Feb 26, 2038 Idorsia
Tryvio US11174247 Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases Nov 06, 2037 Idorsia
Tryvio US11680058 Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan Jul 26, 2038 Idorsia
Tryvio US11787782 Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases Mar 02, 2038 Idorsia
Tryvio US8324232 4-pyrimidinesulfamide derivative Sep 21, 2029 Idorsia



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aprocitentan's patents.

Given below is the list recent legal activities going on the following patents of Aprocitentan.

Activity Date Patent Number
Patent litigations
Initial letter Re: PTE Application to regulating agency 16 May, 2024 US8324232
Patent Term Extension Application under 35 USC 156 Filed 10 May, 2024 US8324232
Mail Patent eGrant Notification 17 Oct, 2023 US11787782
Patent Issue Date Used in PTA Calculation 17 Oct, 2023 US11787782
Recordation of Patent eGrant 17 Oct, 2023 US11787782
Recordation of Patent Grant Mailed 17 Oct, 2023 US11787782
Email Notification 17 Oct, 2023 US11787782
Patent eGrant Notification 17 Oct, 2023 US11787782
Email Notification 28 Sep, 2023 US11787782
Issue Notification Mailed 27 Sep, 2023 US11787782